Xarelto was jointly developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson and Bayer Health Care. Xarelto is an anticoagulant used to reduce the risk of stroke, blood clots, pulmonary embolism, and deep vein thrombosis.
Despite the possible benefits of the drug use, Xarelto has been linked to a substantially increased risk of internal bleeding than its competitors. The risk of bleeding injuries from taking Xarelto have apparently been known for some time, although the drug is still on the market and being prescribed.
Johnson & Johnson promoted Xarelto as a more effective alternative to Coumadin since it allegedly required less frequent monitoring while knowing the drug did not have an approved reversal agent. Without an adequate reversal agent, physicians were unable to control bleeding problems that could arise.
Xarelto is often prescribed because it required less frequent trips to the doctor. However, without the reversal agent, in the event a bleed such as a gastrointestinal bleed occurs, doctors do not have an adequate way to stop the bleeding. This can be fatal.
Reports have shown that Xarelto use has led to uncontrollable bleeding and increased risk of serious injury and death. It is alleged that Johnson & Johnson and Bayer failed to provide warnings and communicate the increased risk of serious injury associated with Xarelto us and continue to promote this drug for large profits without an approved reversal agent.
Xarelto can cause the following bleeding injuries:
- Internal Bleeding
- Gastrointestinal Bleeding
- Kidney Bleeding
- Brain Bleeds
- Death resulting from excessive bleeding
Hundreds of Adverse Event Reports Submitted to FDA Over Xarelto
In 2011, the FDA approved Xarelto to reduce the risk of blood clots, deep vein thrombosis and pulmonary embolisms in patients who underwent knee and hip replacement surgeries, as well as to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Less than one year after the drug was introduced, at least 350 “serious, disabling or fatal” Xarelto-related injuries were reported to the FDA. 
Chelsie King Garza, P.C. is taking cases for those who may have been harmed by or had a loved one due to the use of Xarelto. Chelsie King Garza is experienced in defective products litigation and is here to help ensure compensation for your harms and losses.